TNGX
Tango Therapeutics Inc
NASDAQ: TNGX · HEALTHCARE · BIOTECHNOLOGY
$20.98
-2.96% today
Updated 2026-05-01
Market cap
$3.18B
P/E ratio
—
P/S ratio
51.01x
EPS (TTM)
$-0.87
Dividend yield
—
52W range
$1 – $28
Volume
3.5M
Tango Therapeutics Inc (TNGX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $-24.80M | $70.07M | $-59.53M | $-109.08M | $-117.98M | $-131.50M | $-138.89M |
| Capital expenditures | $1.82M | $1.11M | $1.84M | $7.69M | $1.53M | $754000.00 | $1.05M |
| Depreciation | — | — | — | — | — | — | — |
| Stock-based comp | $1.69M | $1.76M | $7.83M | $14.23M | $19.08M | $28.90M | $26.43M |
| Free cash flow | $-26.62M | $68.97M | $-61.36M | $-116.77M | $-119.51M | $-132.25M | $-139.93M |
| Investing cash flow | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — |
| Net change in cash | — | — | $114.36M | $-81.07M | — | — | — |